| Форма представления | Статьи в российских журналах и сборниках |
| Год публикации | 2025 |
| Язык | английский |
|
Закирова Елена Юрьевна, автор
|
|
Zakirova Elena , автор
|
| Библиографическое описание на языке оригинала |
Samatoshenkov I.V. Extended Toxicity, Genotoxicity, and
Mutagenicity of Combination of
pBudK-coVEGF-coANG and
pBudK-coGDNF Plasmids in
Preclinical Trials. / I.V.Samatoshenkov, A.M., Aimaletdinov, E.Yu. Zakirova, E.L.Kalmykov, R. Khodzhibaev, Y. M. Samatoshenkova, I.M.Ganiev, M.S.Kadyrov, Y.O.Mukhamedshina // Biomedicines. - 2025. - 13. - 1223. https://doi.org/10.3390/
biomedicines13051223 |
| Аннотация |
Chronic lower limb ischemia is a debilitating condition, particularly prevalent
among elderly patients and individuals ineligible for revascularization procedures. Gene
therapy aimed at promoting therapeutic angiogenesis presents a promising alternative
treatment strategy. Objectives: This study evaluated the preclinical safety of a gene therapy
drug composed of the plasmids pBudK-coVEGF-coANG and pBudK-coGDNF in laboratory
animals. Safety assessment followed a single intramuscular injection at a dose 30 times
higher than the proposed therapeutic level. Methods: Acute toxicity was monitored over a
24-h period. Genotoxicity was assessed using the micronucleus test at doses of 200, 1000,
and 5000 μg/kg. Bone marrow cytology was analyzed to detect hematopoietic toxicity.
Delayed toxicity was evaluated over a two-week recovery period. Results: No signs of
acute toxicity were observed, even at the highest dose. The micronucleus test revealed no
genotoxic effects, with no significant increase in micronucleated polychromatic erythrocytes
compared to control groups. Bone marrow erythroblast parameters remained within normal
physiological ranges. Additionally, no delayed adverse effects were detected during the
recovery period. Conclusions: The gene therapy drug demonstrated a favorable preclinical
safety profile, exhibiting no evidence of toxicity or genotoxicity, even at substantially
elevated doses. These findings support the continued development of this therapy as a
potential treatment for chronic lower limb ischemia in patients who are not candidates for
surgical intervention. |
| Ключевые слова |
genetic therapy; ischemic disease; plasmid; glial-derived neurotrophic factor;
vascular endothelial growth factor; angiogenin |
| Название журнала |
Biomedicines
|
| Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на эту карточку |
https://repository.kpfu.ru/?p_id=315770 |
| Файлы ресурса | |
|
|
Полная запись метаданных  |
| Поле DC |
Значение |
Язык |
| dc.contributor.author |
Закирова Елена Юрьевна |
ru_RU |
| dc.contributor.author |
Zakirova Elena |
ru_RU |
| dc.date.accessioned |
2025-01-01T00:00:00Z |
ru_RU |
| dc.date.available |
2025-01-01T00:00:00Z |
ru_RU |
| dc.date.issued |
2025 |
ru_RU |
| dc.identifier.citation |
Samatoshenkov I.V. Extended Toxicity, Genotoxicity, and
Mutagenicity of Combination of
pBudK-coVEGF-coANG and
pBudK-coGDNF Plasmids in
Preclinical Trials. / I.V.Samatoshenkov, A.M., Aimaletdinov, E.Yu. Zakirova, E.L.Kalmykov, R. Khodzhibaev, Y. M. Samatoshenkova, I.M.Ganiev, M.S.Kadyrov, Y.O.Mukhamedshina // Biomedicines. - 2025. - 13. - 1223. https://doi.org/10.3390/
biomedicines13051223 |
ru_RU |
| dc.identifier.uri |
https://repository.kpfu.ru/?p_id=315770 |
ru_RU |
| dc.description.abstract |
Biomedicines |
ru_RU |
| dc.description.abstract |
Chronic lower limb ischemia is a debilitating condition, particularly prevalent
among elderly patients and individuals ineligible for revascularization procedures. Gene
therapy aimed at promoting therapeutic angiogenesis presents a promising alternative
treatment strategy. Objectives: This study evaluated the preclinical safety of a gene therapy
drug composed of the plasmids pBudK-coVEGF-coANG and pBudK-coGDNF in laboratory
animals. Safety assessment followed a single intramuscular injection at a dose 30 times
higher than the proposed therapeutic level. Methods: Acute toxicity was monitored over a
24-h period. Genotoxicity was assessed using the micronucleus test at doses of 200, 1000,
and 5000 μg/kg. Bone marrow cytology was analyzed to detect hematopoietic toxicity.
Delayed toxicity was evaluated over a two-week recovery period. Results: No signs of
acute toxicity were observed, even at the highest dose. The micronucleus test revealed no
genotoxic effects, with no significant increase in micronucleated polychromatic erythrocytes
compared to control groups. Bone marrow erythroblast parameters remained within normal
physiological ranges. Additionally, no delayed adverse effects were detected during the
recovery period. Conclusions: The gene therapy drug demonstrated a favorable preclinical
safety profile, exhibiting no evidence of toxicity or genotoxicity, even at substantially
elevated doses. These findings support the continued development of this therapy as a
potential treatment for chronic lower limb ischemia in patients who are not candidates for
surgical intervention. |
ru_RU |
| dc.language.iso |
ru |
ru_RU |
| dc.subject |
|
ru_RU |
| dc.title |
Extended Toxicity, Genotoxicity, and Mutagenicity of Combination of
pBudK-coVEGF-coANG and pBudK-coGDNF Plasmids in Preclinical Trials. |
ru_RU |
| dc.type |
Статьи в российских журналах и сборниках |
ru_RU |
|
EN 
中文 
ES 
Карта сайта
